Investors

Teligent is a specialty generic pharmaceutical company (NASDAQ: TLGT). Our mission is to be a leading player in the specialty generic prescription drug market.

We currently have 22 Abbreviated New Drug Applications (ANDAs) on file at the FDA, representing a total addressable market of approximately $1.6 billion (IQVIA, June 2018).

We sell a portfolio of prescription topical medicines and a growing number of hospital-based sterile injectable products, including cephalosporins.

"As we execute our strategy, our focus is to scale up and strengthen our business, so we can deliver sustained financial performance."

Damian Finio
CFO

Recent News

Teligent, Inc. Announces First Quarter 2019 Results

BUENA, N.J. , May 06, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic phar...

Learn More

Teligent, Inc. to Hold Conference Call for First Quarter 2019 Results on Monday May 6th, 2019

BUENA, N.J. , May 02, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharm...

Learn More

Teligent Provides Update on Orphan Drug Complete Response Letter

BUENA, N.J. , April 22, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic ph...

Learn More

Stock Information

Copyright West LLC. Minimum 15 minutes delayed.


Investor Overview

There are no items to display.